-
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629 ·
Phase: Phase 2 ·
Ages: 18 Years to 68 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Upland
-
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Bridgeville, Butler, Exton, Langhorne
-
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
NCT07222917 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Media
-
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Bridgeville, Butler
-
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Pennsylvania: Bethlehem
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
NCT04671771 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Sayre
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Beaver, Exton, Indiana, Media
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283 ·
Phase: Phase 3 ·
Ages: 1 Year to 18 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
NCT03633708 ·
Phase: Phase 3 ·
Ages: 0 Years to 18 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
NCT05106387 ·
Phase: Not specified ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
NCT00327860 ·
Phase: Not specified ·
Ages: 6 Months to 22 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
NCT01016613 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Danville, East Stroudsburg
-
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Bethlehem, Exton
-
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Upland
-
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
NCT06712407 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Empagliflozin Treatment in Kidney Transplant Recipients
NCT06013865 ·
Phase: Phase 4 ·
Ages: 19 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Feasibility of The Health Integrated Nutrition and Kidney Wellness Program
NCT07518719 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Ferric Citrate and Chronic Kidney Disease in Children
NCT04741646 ·
Phase: Phase 2 ·
Ages: 6 Years to 18 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
International (Pediatric) Peritoneal Biobank
NCT01893710 ·
Phase: Not specified ·
Ages: 1 Day to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Narberth
-
Kidney Transplant Improvement Through New Exercise Training to Increase Capacity
NCT07446296 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 60 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Oral Iron in Children With Chronic Kidney Disease
NCT03991169 ·
Phase: Phase 4 ·
Ages: 1 Year to 21 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
NCT06422871 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
NCT07494045 ·
Phase: Phase 2 ·
Ages: 1 Month to 17 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Physical Activity in CKD
NCT06624358 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 13 Years to 18 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
NCT04634916 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Butler
-
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
NCT07271186 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Pennsylvania: Bethlehem, West Chester
-
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
NCT06978127 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
The KidneyCARE (Community Access to Research Equity) Study
NCT05497518 ·
Phase: Not specified ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female)
· Pennsylvania: Danville
-
Transformative Research in Diabetic Nephropathy
NCT02986984 ·
Phase: Not specified ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Pennsylvania: Allentown, Philadelphia
-
Transformative Research in Diabetic Nephropathy 2.0
NCT07444203 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Transforming Hemodialysis-Related Vascular Access Education
NCT05997875 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Virtual Reality in End Stage Kidney Disease
NCT06356168 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Philadelphia